Birmingham Hip Resurfacing in Birmingham — Cost, Top Hospitals & Success Rates | MyMedicPlus

Birmingham Hip Resurfacing (BHR) is a type of hip arthroplasty that preserves the femoral head and neck by re-surfacing — rather than removing — the articular surface of the femoral head and fitting a metal cup into the acetabulum (hip socket). Developed by Derek McMinn in Birmingham, UK, in the mid-1990s, BHR uses a metal-on-metal (MoM) bearing surface in a cobalt-chromium-molybdenum alloy. The device received CE marking in Europe in 1997 and FDA approval in the US in 2006, and became widely adopted as a bone-conserving alternative to total hip replacement (THR) for younger, more active patients.

The surgical technique involves exposing the hip through a posterior or anterolateral approach, preparation of the acetabulum with hemispherical reamers and press-fitting or cement-fixation of the acetabular cup, then resurfacing the femoral head with a guide wire and coring reamers before cementing the femoral head cap in place. The natural femoral neck is preserved, which is the key bone-conserving advantage and the reason the procedure is favoured for younger patients who may require revision surgery later in life.

From a biomechanical perspective, BHR restores hip kinematics more naturally than standard THR because it maintains the femoral head-neck offset, preserves proprioceptive nerve endings in the femoral head, and has a larger-diameter bearing surface reducing dislocation risk. The bone stock in the proximal femur is preserved for potential future THR if needed.

Clinical outcomes data spanning 15-20 years show registry-confirmed survival rates of 85-95% at 10 years for well-selected patients (young active males with good bone quality). However, concerns about metal ion release from MoM bearings — cobalt and chromium ions — and their association with pseudotumours (aseptically lymphocyte-dominated vasculitis-associated lesions, ALVAL) and systemic metal toxicity have significantly reduced the use of BHR globally since 2010-2012.

Birmingham Hip Resurfacing is primarily indicated for advanced hip osteoarthritis (OA) — degenerative loss of articular cartilage causing progressive pain, stiffness, and functional limitation unresponsive to conservative management. It is particularly suited to younger patients (typically under 60 years) with primary OA or post-traumatic OA where bone stock is excellent, and who wish to return to high-impact activities.

Other indications include avascular necrosis (osteonecrosis) of the femoral head in the early stages where the femoral head can be resurfaced without structural collapse, hip dysplasia with secondary OA in patients with adequate bone density, and ankylosing spondylitis with secondary hip arthritis in younger patients. BHR is not appropriate for inflammatory arthropathies with osteopenia, as cement fixation in osteoporotic bone carries a high risk of femoral neck fracture.

Ideal BHR candidates are males under 60 years of age with primary hip osteoarthritis, good bone stock, normal-to-large femoral head size (head diameter above 46-50 mm), no evidence of osteopenia or significant femoral head cysts, and a desire to return to high-impact sporting activities. Male sex is a key predictor of outcome because females have a significantly higher rate of adverse local tissue reactions (ALTR) and pseudotumour formation with MoM bearings, and BHR is now generally recommended only for male patients by most guidelines.

Contraindications include female sex (due to ALTR risk), severe osteoporosis (T-score below -2.5), large femoral head cysts (cyst diameter above 1 cm), severely deformed femoral head not amenable to resurfacing, renal impairment (impaired metal ion clearance increases systemic toxicity risk), known metal hypersensitivity, and any condition associated with elevated metal ion levels. Elevated baseline cobalt or chromium levels should be investigated before implantation.

The BHR-specific technique uses the trademarked Birmingham Hip Resurfacing system (Smith+Nephew) with its specific guide wire and jig system. Other metal-on-metal resurfacing systems such as the Conserve Plus (Wright Medical), Durom (Zimmer), and ASR (DePuy) were also used historically, but most have been withdrawn or their use severely curtailed due to higher failure rates. The BHR system retains the best long-term outcome data among MoM resurfacing systems.

Surgical approach options include the posterior approach, anterior approach, and anterolateral approach. The posterior approach provides excellent femoral head exposure but has a historically higher dislocation rate; the larger head of BHR mitigates this risk. Cement fixation of the femoral component and press-fit (or hybrid) fixation of the acetabular cup is the standard. Component positioning with optimal cup inclination (40-45 degrees) and anteversion (15-20 degrees) is critical to minimise edge loading and metal ion generation. The treating surgeon individualises the chosen technique based on patient anatomy, the extent and nature of the underlying condition, available equipment, and the balance of procedural benefit against risk — a decision made in consultation with the patient following a thorough informed consent discussion covering all available options. The treatment team works closely with patients and their families throughout the entire care pathway, from initial diagnosis and pre-operative preparation through to post-operative recovery and long-term follow-up.

BHR preserves proximal femoral bone stock, which is a significant advantage for young patients who may need revision surgery 20-30 years post-implantation, as conversion to standard THR is technically easier and bone-preserving. The large femoral head diameter (44-54 mm) provides near-zero dislocation risk compared to 1-3% with standard small-head THR. Patients typically return to running, cycling, hiking, and even moderate-impact sports within 6 months.

At 10 years, registry data show 85-95% implant survival in well-selected male patients. BMI patients report high functional scores (Oxford Hip Score typically 40-45/48) and high satisfaction rates. Metal ion levels (cobalt, chromium) should be monitored annually; well-functioning BHR devices typically produce levels below 7 ppb at 1 year, which is below the nationally recommended follow-up threshold.

Metal ion release is the specific and most concerning complication of BHR. Elevated cobalt and chromium ions cause adverse local tissue reactions (ALTR), including pseudotumours — soft tissue masses around the hip representing granulomatous inflammation and necrosis — in 1-5% of patients. Revision rates for ALTR/pseudotumour are higher in female patients (3-5 times higher than males), driving the sex-specific guidance. Systemic metal toxicity (cardiomyopathy, neuropathy, thyroid dysfunction) is a concern at very high ion levels but rare with well-positioned components.

Femoral neck fracture occurs in 1-2% of cases, most often in the first 6-12 months post-operatively due to osteonecrosis from thermal injury during reaming or vascular disruption. Component malposition with excessively steep or anteverted acetabular cups accelerates edge loading and metal ion generation, increasing ALTR risk. Standard surgical risks including infection (0.5-1%), nerve injury, DVT/PE, and wound complications also apply.

Post-operative recovery involves physiotherapy mobilisation on day 1, hospital discharge at 3-5 days, and weight bearing as tolerated from the first day with crutches for 6 weeks. Metal ion testing (cobalt, chromium serum levels) is mandatory at 1 year post-implantation and then annually, following MHRA (UK) and FDA guidance for metal-on-metal implants. MARS MRI (Metal Artefact Reduction Sequence) of the hip is performed if ion levels are elevated or symptoms develop.

Return to impact sports is typically permitted at 6-12 months. Long-term follow-up with ASA/MHRA guidelines recommends annual clinical review and metal ion monitoring for the life of the implant. Patients should carry an implant identification card noting the device type and batch number for any emergency MRI considerations.

Birmingham Hip Resurfacing costs $25,000-$50,000 in the United States, comparable to total hip replacement but with higher implant costs. UK NHS funding for BHR is available at designated orthopaedic centres; private costs in the UK range from £12,000-£20,000. The procedure requires a surgeon with specific BHR training and certification (Smith+Nephew credentialing programme).

In India and Thailand, BHR at JCI-accredited orthopaedic centres costs $7,000-$14,000, representing 60-70% savings. The BHR implant must be verified as genuine (Smith+Nephew or an approved system) and not a lower-quality counterfeit — patients should confirm implant provenance before proceeding. Centres such as Apollo (Chennai/Delhi), Max Healthcare (Delhi), and Fortis (multiple sites) have accredited orthopaedic surgeons performing BHR with verifiable implant traceability. International patients should factor in the cost of pre-operative testing, post-operative accommodation during recovery, translation services where required, and travel insurance including medical evacuation cover when planning overseas medical treatment.

Total hip replacement (THR) with standard femoral head sizes (28-36 mm) is the gold-standard alternative and is appropriate for most patients with hip arthritis regardless of age. Modern uncemented THR with highly cross-linked polyethylene bearings achieves 95%+ survival at 10 years and can be performed in patients who would not be suitable for BHR. Ceramic-on-ceramic THR offers low wear and ion generation in younger active patients as a metal-free alternative.

Hip arthroscopy for early hip impingement (FAI) and labral repair may address younger patients with pre-arthritic hip pain, potentially delaying the need for replacement. Periarticular hip injections (corticosteroid, PRP) and physiotherapy for hip OA provide symptomatic relief but do not address structural damage. Osteotomy (periacetabular or proximal femoral) may correct anatomical causes of OA in selected younger patients, delaying arthroplasty.